Last reviewed · How we verify
NCT03223363
A New Birth Weight Prediction in Chinese Population
NA trial testing 2D and 3D ultrasonography in Birth Weight in 10,000 participants. Status unknown.
1 September 2020
Quick facts
| Lead sponsor | Nanfang Hospital, Southern Medical University |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | factorial |
| Masking | quadruple |
| Primary purpose | diagnostic |
| Enrollment | 10,000 |
| Start date | 1 September 2016 |
| Primary completion | 1 September 2020 |
| Estimated completion | 1 September 2021 |
| Sites | 1 location across China |
Drugs / interventions tested
- 2D and 3D ultrasonography
Conditions studied
- Birth Weight — all drugs for Birth Weight →
Sponsor
Nanfang Hospital, Southern Medical University
Who can join
Eligibility, female only, with Birth Weight. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To determine the value of principal component analysis in the combined method of three-dimensional ultrasonography assessing fetal limb volume and circumference and conventional two-dimensional ultrasonography for prediction of birth weight in southern Chinese population.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03223363
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Birth Weight
Currently open trials in the same condition.
- NCT06487286 — Levels of Visfatin/NAMPT in Human Milk · recruiting
- NCT06125860 — BEP Targeting Strategies in Ethiopia · NA · recruiting
- NCT05708183 — Healthy Mums, Healthy Babies: Multiple Micronutrient Supplementation in Ethiopia · recruiting
- NCT06542718 — Studying Phenotypes of Gestational Diabetes Mellitus in an Asian Pregnant Cohort · recruiting
- NCT06963528 — Gestational Diabetes Monitoring and Management · active not recruiting
Other Nanfang Hospital, Southern Medical University trials
Trials by the same sponsor.
- NCT07091994 — A Trial of Edaravone Dexborneol in Acute Ischemic Stroke With Active Malignancy · Phase 4 · not yet recruiting
- NCT06444022 — hAESCs Prevent Acute Graft-versus-host Disease After Hematopoietic Stem Cell Transplantation · Phase 1 · withdrawn
- NCT07537777 — Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted T · Phase 2 · not yet recruiting
- NCT07481032 — Effect of Fufang Biejiaruangan Combined With Antiviral Therapy on the Incidence of Hepatocellular Carcinoma in Patients · NA · not yet recruiting
- NCT07511894 — Beta-Blockers on the Efficacy of Neoadjuvant Immunotherapy for Gastric Cancer · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03223363 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Nanfang Hospital, Southern Medical University
- Last refreshed: 21 July 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03223363.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing